Dr. Amit Patel (our CEO) and his family found Atnahs and name it in honour of their grandmother, Shanta.
We acquire Marlborough Pharmaceuticals, which owns Gynest®, Sinepin® and Welldorm® in the UK, and set about building a platform dedicated to acquiring, marketing and developing mature branded pharmaceuticals globally.
We acquire Dipentum® from UCB, and expand into Western Europe, Australasia and Canada.
We open an agency office in Sydney, Australia to service our Australasian markets.
We acquire Naproxen Suspension from Pediapharm.
We also acquire a majority stake in Pharmanovia, a specialty pharma business focused on mature product development and located in Copenhagen, Denmark.
We acquire Famvir® from Novartis and expand into Russia. Pharmanovia launches Dropizol® in the rest of the Nordics and Germany.
We acquire the remainder of Pharmanovia.
We acquire Synacthen® from Mallinckrodt.
We sell a majority stake to Triton to support us in our future growth strategy.